NCT02926976

The Optimal Treatment for Treatment-resistant Schizophrenia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Shanghai Mental Health Center · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The Optimal Treatment for Treatment-resistant Schizophrenia

Detailed description

To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Risperidone with Clozapine	Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
DRUG	Aripiprazole with Clozapine	Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
DRUG	sodium valproate with Clozapine	sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
DEVICE	modified electroconvulsive therapy(MECT) with Clozapine	modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
DEVICE	Magnetic seizure therapy(MST) with Clozapine	Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
DEVICE	clozapine	clozapine may be used in the treatment of treatment-resistant schizophrenia

Timeline

• Start date: 2016-11-01
• Primary completion: 2019-09-01
• Completion: 2019-09-01
• First posted: 2016-10-06
• Last updated: 2019-03-13

Locations

1 site across 1 country: China